Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12057465 | 0.82 | MDM2 (0.33) | — | |
| SCHEMBL13715831 | 0.78 | KDM4E (0.51) | NPC1RAB9APIM1SMN1; SMN2PIM3 | |
| SCHEMBL13715632 | 0.78 | NPC1 (0.58) | NPC1RAB9AADORA3PIM1ADORA2A | |
| SCHEMBL13715839 | 0.75 | PIM1 (0.43) | PIM1PIM3 | |
| SCHEMBL13715594 | 0.75 | GOT1 (0.40) | NPC1RAB9AADORA3PIM1ADORA2A | |
| SCHEMBL29245688 | 0.74 | GCK (0.42) | RAB9ASMN1; SMN2 | |
| SCHEMBL13686685 | 0.74 | — | — | |
| SCHEMBL10912483 | 0.72 | NPC1 (0.58) | NPC1RAB9AADORA3PIM1ADORA2A | |
| SCHEMBL13715672 | 0.72 | SMN1; SMN2 (0.57) | NPC1RAB9AADORA3PIM1ADORA2A | |
| SCHEMBL10380209 | 0.72 | ALDH1A1 (0.36) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084619-B2 | Gas generant compositions | TK HOLDINGS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110046390-A1 | Gas Generant Compositions | GANTA SUDHAKAR R | 2011-02-24 | — | — | US | disclosed |
| US-7847102-B2 | generating fuel, is defined as a compound having the structural formula of R3 R1 R2, wherein R1 is a urea group, R2 is a tetrazolyl group with a C N bond to the urea group, and R3 may be defined as a non-tetrazolyl, triazolyl, heterocyclic, heterocyclic amine, aliphatic, aliphatic amine, aryl, alkyl, | TK HOLDINGS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2021306-A2 | GAS GENERANT COMPOSITIONS | TK Holdings Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080154044-A1 | Gas generant compositions | JOYSON SAFETY SYSTEMS ACQUISITION LLC | 2008-06-26 | — | — | US | disclosed |
| WO-2007130676-A2 | GAS GENERANT COMPOSITIONS | TK HOLDINGS, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080154044-A1 | Gas generant compositions | GPR139, CBR1, UQCRB | NPC1 2153/4885RAB9A 2230/4885ADORA3 1466/4885 |
| US-20110046390-A1 | Gas Generant Compositions | GPR139, CBR1, UQCRB | NPC1 2153/4885RAB9A 2230/4885ADORA3 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.